Amgen Inc.
AMGN Healthcare Drug Manufacturers - General NASDAQ
$329.89
$-10.27 (-3.02%)
Open: $340.46 | High: $340.87 | Low: $328.71 | Prev Close: $340.16
Market Cap: $177.64B
Volume: 2.7M | Avg: 2.9M
Last updated: December 05, 2025 at 10:00 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 465
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 25.51 |
| P/B Ratio | 18.45 |
| P/S Ratio | 4.94 |
| EPS | $12.93 |
| Beta | 0.45 |
| Shares Outstanding | 538.48M |
| 52-Week High | $346.38 |
| 52-Week Low | $253.30 |
| SMA 50 | $310.82 |
| SMA 200 | $296.57 |
| Dividend Yield | 2.89% |
| Annual Dividend | $9.52 |
| Next Earnings | February 03, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 66.1% |
| Operating Margin | 24.1% |
| Net Margin | 19.5% |
| ROE | 96.2% |
| ROA | 7.8% |
| Debt/Equity | 5.67 |
| Current Ratio | 1.28 |
| Quick Ratio | 0.99 |
Balance Sheet
| Total Assets | $91.84B |
| Total Liabilities | $85.96B |
| Total Equity | $5.88B |
| Cash | $11.97B |
| Total Debt | $60.10B |
| Net Debt | $48.13B |
Income Statement
| Revenue | $33.42B |
| Gross Profit | $20.57B |
| Operating Income | $7.26B |
| Net Income | $4.09B |
| EBITDA | $13.36B |
| Revenue/Share | $66.84 |
Cash Flow
| Operating CF | $11.49B |
| CapEx | $1.10B |
| Free Cash Flow | $10.39B |
| Book Value/Share | $17.88 |
| Tangible Book/Share | $-59.84 |
| Equity/Share | $17.88 |
Technical Indicators
| RSI (14) | 53.93 Neutral |
| MACD |
9.28
Signal: 10.44
|
| Volatility | 31.17% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +12.1% |
| Sharpe Ratio | 0.58 Fair |
| Volatility (Ann.) | 28.18% Moderate |
| AMGN (1Y) | +12.1% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | +0.24% |
Sector Comparison (Healthcare)
| Metric | AMGN | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 25.51 | 31.3 | 51% |
| P/B Ratio | 18.45 | -0.87 | 93% |
| ROE (%) | 96.19% | 8.34% | 93% |
| Net Margin (%) | 19.48% | 9.89% | 75% |
| Stock Score | 465 | 505.0 | 27% |
| 1Y Return (%) | +12.10% | +4.29% | 64% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | $329.89 | $341.38 | $340.86 | $340.66 | $310.82 | $296.57 | 53.93 | 9.28 | 31.17% | 3695846 | Weak Short | Bullish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the AMGN stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| AMGN | Why Is Amgen (AMGN) Up 8% Since Last Earnings Report? | Neutral | zacks.com | Read More |
| AMGN | 3 Potential Mid-Cap Biotech Buyout Targets In 2026 | Neutral | seekingalpha.com | Read More |
| AMGN | Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Neutral | seekingalpha.com | Read More |
| AMGN | Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| AMGN | Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza | Neutral | feeds.benzinga.com | Read More |
Company Information
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| CEO | Robert A. Bradway |
| Employees | 28000 |
| Country | US |
| IPO Date | 1983-06-17 |
| Exchange | NASDAQ |
| Website | https://www.amgen.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category